Tesamorelin 10mg 3ml Research Peptide UK

For research use only. Not for human consumption.

Tesamorelin (TH9507) — 10mg | Pre-Mixed 3ml Vial | ≥99% Purity | COA Verified | UK Dispatch

Tesamorelin is a synthetic 44-amino acid analogue of endogenous human Growth Hormone-Releasing Hormone (GHRH 1–44), distinguished by the addition of a trans-3-hexenoic acid group at the N-terminus. This structural modification significantly increases resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), extending the peptide's stability and half-life in biological research environments compared to native GHRH. Tesamorelin is the only FDA-approved compound in the GHRH analogue class, receiving approval in 2010 under the brand name Egrifta for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy — providing one of the most robust clinical evidence bases of any research peptide in the GH/IGF-1 axis category.

This listing features a pre-mixed, ready-to-use 3ml vial containing 10mg of research-grade Tesamorelin, providing consistent laboratory-ready concentration for precise experimental workflows.

Mechanism of Action in Research Tesamorelin acts as a selective GHRH receptor (GHRHR) agonist, binding to pituitary GHRH receptors to stimulate endogenous GH synthesis and pulsatile secretion via Gs protein-coupled cAMP/PKA signalling cascades. In research models this produces downstream:

• Stimulation of the GH/IGF-1 axis with subsequent IGF-1 elevation
• Enhanced lipolysis in visceral adipose tissue through GH-mediated fat mobilisation pathways
• Preservation of pulsatile GH secretion patterns — unlike continuous GH administration, GHRH analogues maintain physiological GH pulse architecture
• Modulation of endocrine feedback loops including somatostatin-mediated negative regulation

Key Research Areas Tesamorelin is one of the most clinically validated peptides in the GHRH class, with significant preclinical and clinical data across multiple research domains:

• Visceral adipose tissue & lipodystrophy — Phase II and III clinical trial data demonstrate statistically significant reductions in visceral adipose tissue volume; the foundational research area and basis of FDA approval in HIV-associated lipodystrophy
• GH/IGF-1 axis modulation — widely used in endocrinology research to study GHRH receptor signalling kinetics, pituitary GH secretion dynamics, downstream IGF-1 regulation, and somatotropic axis feedback mechanisms
• Cognitive function research — multiple clinical studies have investigated tesamorelin's effects on cognitive performance in older adults; a double-blind RCT demonstrated improvements in executive function and verbal memory in cognitively normal older individuals, linked to IGF-1 elevation and possible neuroprotective mechanisms
• Metabolic & body composition research — studied for effects on lipid metabolism, visceral vs subcutaneous adipose tissue distribution, insulin sensitivity, and cardiometabolic risk markers in aging and metabolic disease models
• Growth hormone deficiency models — used as a tool compound in comparative research examining GH secretagogue classes (GHRH analogues vs GHSR agonists such as ipamorelin), receptor pathway selectivity, and GH pulse amplitude optimisation
• DPP-4 resistance & peptide stability — the trans-3-hexenoic acid modification makes tesamorelin a model compound for studying N-terminal peptide engineering strategies aimed at improving proteolytic stability
• Comparative GH secretagogue studies — frequently paired with CJC-1295 (without DAC) to examine GHRH receptor pathway activity, or with ipamorelin for dual-receptor GH synergy studies investigating amplified GH secretion versus individual secretagogue effects
• Neuroendocrine & ageing research — investigation of age-related GH decline (somatopause), GH pulse attenuation, and restoration of youthful GH secretory profiles in ageing models

Product Specifications

• CAS Number: 218949-48-5
• Synonyms: TH9507, Egrifta (brand)
• Full Sequence: Trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂
• Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
• Molecular Weight: 5,135.86 g/mol
• Amino Acids: 44 (plus trans-3-hexenoic acid N-terminal modification)
• PubChem CID: 16137828
• Quantity: 10mg per vial
• Volume: 3ml (pre-mixed)
• Purity: ≥99% (HPLC & MS verified)
• Form: Pre-mixed solution
• Appearance: Clear to off-white solution
• Solubility: Soluble in sterile/bacteriostatic water; introduce water slowly against the glass wall due to high molecular weight
• Storage: Refrigerate at 2–8°C once mixed. Protect from light at all stages — the N-terminal trans-3-hexenoic acid modification is light-sensitive. Do not freeze reconstituted solution. Avoid repeated freeze-thaw cycles. Lyophilised (unmixed) stable at −20°C for up to 24 months.
• Shelf life (pre-mixed): Use within 28 days. Inspect before each use — discard if discoloured or particulate present.
• Dispatch: Fast UK dispatch. Orders placed before 2pm dispatched same working day.

Concentration At 10mg in 3ml: concentration = 3.33mg/ml (3,333mcg/ml)

COA Available: Every batch independently third-party tested. Certificate of Analysis available on our Lab Reports page before ordering.

All products sold by Ultra Peptides are strictly for laboratory and in-vitro research purposes only. Not intended for human or veterinary use outside of licensed clinical contexts. Not approved by the MHRA for general medical or therapeutic application in the UK. By purchasing this product you confirm your intended use is for legitimate scientific research conducted in a controlled laboratory setting.